CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CCTG HN13 clinical trial has successfully been awarded $1,602,675 in the Spring 2023 CIHR funding competition to investigate improving head and neck tumour and symptom control in patients who are unable to tolerate curative radiotherapy.
The CEC5 (ALLIANCE A221208) Phase II Study of Corticosteroid + Bevacizumab vs Corticosteroid + Placebo (BeST) for Radionecrosis after Radiosurgery for Brain Metastases trial has permanently closed.
Please save the date for the 2024 Annual Spring Meeting of Participants which will be held at the Chelsea Hotel from Friday, May 3 to Sunday, May, 5.
The spring meeting is the place for the network members to share ideas, work on trial concepts or ongoing studies, hear about the latest tools and approaches in cancer clinical research, and determine future research directions for the group. More information will be coming soon so stay tuned!
New ways to connect with CCTG have recently launched. CCTG is now on Instagram and Threads. The Threads app is built on the Instagram network and we have begun accounts on both platforms. Instagram and Threads is where we hope everyone in our Cancer research community can come together to discuss our research and support each others work. You can follow and connect directly with our accounts and we will make sure to follow you back.
An international study has now opened in Canada that will evaluate if immunotherapy prevents tumour recurrence or spread in early-stage endometrial cancer. The researchers want to compare the effects of a new drug in combination with radiation therapy compared to the current standard treatment of radiation therapy alone for endometrial cancer.
Dr. Joseph Pater has been recognized for a lifetime of work in cancer research with his appointment as an Officer of the Order of Canada. The honor acknowledges the impact of his dedication to clinical research which has improved the lives of Canadians with cancer.
